News

Announced FDA clearance of IND application for novel IRAK4 degrader GS-6791/NX-0479, enabling collaboration partner Gilead to initiate Phase 1 trial SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- ...
Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers hope. Click for my GILD and KYMR update.
US antivirals specialist Gilead Sciences today announced a strategic partnership agreement with the Global Fund to Fight AIDS ...
Shares of Nurix Therapeutics rose after the biopharmaceutical company reported that revenue in its fiscal second quarter more than tripled from a year ago. The stock was up 11%, at $14.59, in ...
GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and ...
The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...
Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader alongside details of the selection of a follow-up prospect and a $750 ...
Kymera Therapeutics, Inc. KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader ...
Nonetheless, the firm concluded that Kymera’s partnerships with Sanofi and Gilead continue to “drive value.” Don't miss out ...
Kymera Therapeutics may have signed a $750 million deal with Gilead, but the Watertown biotech also suffered a setback in its partnership with Sanofi.
Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular glue programme, as Sanofi buys into another.
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.